Skip to the content
Please enable JavaScript in your browser to complete this form.
Evaluation Form
Thank you for your active participation at the Expert Meeting ‘
Navigating the Transformative Era of Endometrial Cancer Treatment
’. Your feedback is important to us and will help improve future meetings. We appreciate you taking a moment to complete this form.
Full name
*
1. The meeting was well organised and convenient to my schedule.
*
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Strongly agree
Item #1 Strongly agree
Agree
Item #1 Agree
Neutral
Item #1 Neutral
Disagree
Item #1 Disagree
Strongly disagree
Item #1 Strongly disagree
2. The meeting served as an effective forum for discussing the optimisation of current molecular testing strategies and the role of IO in Hong Kong’s treatment landscape.
*
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Strongly agree
Item #1 Strongly agree
Agree
Item #1 Agree
Neutral
Item #1 Neutral
Disagree
Item #1 Disagree
Strongly disagree
Item #1 Strongly disagree
3. The meeting served as an effective forum to review the DUO-E trial outcomes and discuss how these findings translate to perceptions of PARPi + IO combination for 1L advanced/recurrent endometrial cancer.
*
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Strongly agree
Item #1 Strongly agree
Agree
Item #1 Agree
Neutral
Item #1 Neutral
Disagree
Item #1 Disagree
Strongly disagree
Item #1 Strongly disagree
4. After the meeting, I believe the utilisation of durvalumab + olaparib would be the new combination for pMMR advanced/recurrent endometrial cancer.
*
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Strongly agree
Item #1 Strongly agree
Agree
Item #1 Agree
Neutral
Item #1 Neutral
Disagree
Item #1 Disagree
Strongly disagree
Item #1 Strongly disagree
5. Did the meeting include all relevant discussion points and topics crucial for the PARPi + IO combination in 1L advanced/recurrent endometrial cancer?
*
Yes
No
5. No, please elaborate
*
6. Do you have any additional feedback / comments?
Yes
No
6. Yes, please elaborate
*
Submit